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Introduction
Long-term survival rates are increasing for various forms
of cancer in many countries. It would be highly desirable
that cancer registries could detect such increases as timely
as possible. However, traditional estimates of long-term
survival, which are derived by cohort-based types of
analysis [1-3], essentially reflected the survival expecta-
tions of patients diagnosed many years ago. A few years
ago, a new methodology of survival analysis, denoted
period analysis, has been introduced that enables more
up-to-date estimates of long-term survival rates [4, 5].
This review gives a short outline of the new methodology,
its statistical background, empirical evaluation, compu-
tational realization and applications.
The period principle
The principle of period analysis of survival is very simple.
Period estimates of survival are derived for the most
recent period for which data on cancer incidence and
survival are available in the registry. For that purpose,
all observations of patients included in the study are left
truncated at the beginning of that period in addition to
being right censored at its end. The principle and its
differences from traditional survival analysis are
illustrated in Figure 1. 
Assume, a cancer registry has collected data from cancer
patients diagnosed between the years 1980 and 2000, and
that all patients have been followed up with respect to
vital status until the end of the year 2000. Then, the most
up-to-date estimate of 5-year-survival by traditional
"cohort analysis" would pertain to patients diagnosed in
1995 and followed from 1995 to 2000. Analogously, the
most up-to-date estimates of 10-, 15- and 20-year survival
would pertain to patients diagnosed in 1990, 1985, and
1980, respectively, taking their survival experience from
diagnosis to the year 2000 into account (black frames in
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Figure 1). This implies that the long-term survival
estimates obtained from this database at the beginning of
the 21st century might be quite out of date.
By contrast, the period approach would exclusively
reflect the survival experience in the year 2000, regardless
whether 5-, 10-, 15- or 20-year survival estimates are
determined. Survival during the 1st year following
diagnosis would be obtained from patients diagnosed in
1999 and 2000, conditional survival during the 2nd year
following diagnosis would be obtained from patients
diagnosed in 1999 and 1998, and so on, until conditional
survival experience in the 20th year following diagnosis
which would be obtained from patients diagnosed in 1980
and 1981 (grey frame in Figure 1). Cumulative survival
rates are then obtained by multiplication of those
conditional survival rates in the usual manner.
What the period principle achieves
Comprehensive empirical evaluation carried out within
the last few years has shown that:
– long-term period survival estimates are much more
up-to-date than traditional estimates of long-term
survival estimates in case of improvements in survival
over time,
– period survival estimates are identical to traditional
survival estimates if prognosis does not change over
time,
– long-term period survival estimates for a given period
quite closely predict the survival rates observed many
years later for patients diagnosed in that period,
– period analysis advances detection of trends in 5-, 
10-, 15- and 20-year survival rates by almost 5, 10, 15
and 20 years, respectively, compared to traditional
cohort survival analysis.
These patterns have been consistently shown for all
of the most common forms of cancer among both adults
[6-9] and children [10]. Although somewhat more up-to-
date survival estimates can also be obtained by traditional
survival analysis through the inclusion of more recently
diagnosed patients who could not be under observation
for the entire follow-up period of interest by the closing
date of follow-up, even those "complete estimates" are
typically much less up-to-date than the estimates that can
be obtained by period analysis [7]. In case of very rapid
increases of long-term survival rates over time, even the
period estimates tend to remain slightly "too pessimistic",
however, albeit much less so than the survival estimates
obtained by traditional approaches.
As an example, figures 2 shows the most recent
period estimates of 20-year relative survival curves for
the year 2000 for women diagnosed with cancer in the
United States below age 75 compared to the most recent
5-, 10-, 15- and 20- year relative survival curves obtained
by cohort analysis (relative survival is obtained as the
ratio of observed survival and expected survival in the
absence of cancer, and it thereby reflects "net mortality"
due to the cancer [3]). These estimates were derived from
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Figure 1. Principle of derivation of recent period estimates (grey frame) versus traditional cohort estimates (black frames) of long-term survival
rates illustrated in the context of a cancer registry with incidence and follow-up data from 1980 to 2000. The numbers within the cells indicate the
years of follow-up since diagnosis
the 1973-2000 public use database of the Surveillance,
Epidemiology, and End Results (SEER) Program of the
United States National Cancer Institute issued in April
2003 [11]. Relative survival was calculated according to
the Hakulinen method [12]. The most recent period
estimates of 5-, 10-, 15- and 20-year relative survival which
can be obtained from a single survival curve, are 70, 64, 60
and 57%, respectively (grey curve in figure 2), whereas the
most recent cohort estimates, which are obtained from
different survival curves (black curves in figure 2), are
between 2 and 10 percent units lower.
How to carry out period analysis
Period analysis can be conveniently carried out for both
absolute (observed) and relative survival rates using
publicly available SAS macros. Two macros are currently
available, one called "period" [13] which can be used for
calculation of absolute survival and for calculation of
relative survival according to the so-called Ederer II
method [14]. The other macro, called "periodh" [15], can
be used for absolute survival and for relative survival
calculated according to the Hakulinen method [12]. Both
macros use a life-table approach with one-year intervals of
follow-up. Numbers of deaths and persons at risk by
follow-up year, as well as point estimates and standard
errors (calculated according to Greenwood's formula
[16]) of cumulative absolute, expected and relative
survival rates can be provided. Apart from their use for
period analysis, the macros can also be used for
traditional (cohort-wise) life table analysis of survival.
The macros can be run with the SAS statistical
software package version 8 or older. The macros and
their documentation can be downloaded free of charge
from the statistical archive network maintained by the
Department of Medical Informatics, Biometry and
Epidemiology at the University of Erlangen-Nuremberg
(http://www.imbe.med.uni-erlangen.de/issan/SAS/
period/period.htm). The source code of the macros is
open code under the conditions of the GNU-GPL license
[17].
Recent Applications
In recent years, the period analysis approach has been
adopted by an increasing number of countries to provide
more up-to-date long-term cancer patient survival
statistics. Period estimates of long-term cancer patient
survival rates have now been reported for cancer patients
in Finland [18], Estonia [19], Germany [20-24], the United
Kingdom [25], and the United States [10, 26] and
pertinent analyses are under way in a number of
countries, including, among others, Denmark, Sweden,
the Netherlands and Australia. Furthermore, period
analysis is currently carried out in the ACCIS project,
a collaborative project on childhood cancer survival in
Europe [27]. Some cancer registries, such as the nation-
wide Finnish Cancer Registry and the nationwide German
Childhood Cancer Registry, have already implemented
period analysis as the standard tool for their annual
reports [28, 29].
In all of the published applications, long-term
survival estimates obtained by period analysis were
considerably higher than long-term survival estimates
obtained by traditional survival analysis for those forms of
cancer for which major improvement in prognosis has
been achieved over time. The advantages of period
analysis compared to traditional cohort analysis have
been found to be particularly large for childhood cancers,
given the strong improvement in prognosis achieved by
advancements in therapy for many forms of childhood
cancer during the past decades. For example, recent
period estimates of 15-year survival of children with acute
lymphocytic leukemia and acute non-lymphocytic leu-
kemia in Germany were 77% and 57%, respectively,
compared to estimates of 69% and 36%, respectively,
obtained by traditional cohort analysis [23].
Discussion
The period analysis methodology provides a useful tool to
disclose progress in long-term survival of cancer patients,
which has meanwhile been achieved for a number of
cancers, and which is expected to continue in the future,
in a more timely manner than traditional methods of
survival analysis.
Like other methods of descriptive survival analysis,
the period method does not by itself disclose the reasons
for improvements in survival rates over time. Although
such improvements are often due to advancements in
therapy, as in the case of common forms of childhood
cancers, they are sometimes also due to earlier diagnosis
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Figure 2. Recent 5-, 10-, 15- and 20-year relative survival curves for
women diagnosed with any form of cancer below age 75 in the United
States according to period analysis for the year 2000 (grey line) or
according to cohort analysis (pertaining to patients diagnosed in 1995,
1990, 1985 and 1980, respectively) (black lines, from top to bottom)
(e.g. in the context of introduction of new screening
programs, such as screening for breast cancer by mammo-
graphy), and they may even be due to overdiagnosis in
certain instances (an issue that is of concern, for example,
in the context of PSA screening for prostate cancer).
However, this caveat has to be kept in mind in the
interpretation of any survival statistics, and it is not
specific to survival estimates obtained by period analysis.
This review focused on use of the period approach
for descriptive survival analysis. The period approach
may also be used in more complex analyses, such as
multivariate modeling of survival rates [30]. Further
developments may include the combination of period
analysis with modeling of recent time trends or with other
modeling approaches [e.g. 31, 32] to come up with even
more up-to-date survival figures. However, the potential
benefits of such extensions will have to be weighed against
the increased complexity of methods and less forward
interpretation of results.
Although the period approach to survival analysis
may appear to be somewhat more difficult to digest and
to communicate on first view than the traditional cohort-
based survival analysis, the period approach is a straight-
forward and simple concept that has been successfully
used for decades in other types of health statistics. In
particular, the possibly most commonly cited and used
parameter in health statistics, the life expectancy, is
a classical period measure, as it is commonly derived
from period life tables. Just like the life expectancy
(derived from period life tables) quantifies the average
length of life of a cohort of newborns on the basis of the
(conditional) survival rates at various ages observed
during some recent period (such as the most recent
calendar year for which data are available), the period
estimates of cancer patient survival quantify the survival
expectations of newly diagnosed cancer patients on the
basis of the most recently observed (conditional) survival
rates in various years following diagnosis. There is no
reason why period estimates should be less accepted for
cancer survival rates than they have long been for the
life expectancy.
In an era of steadily increasing survival rates of
patients with many forms of cancer, provision of the most
up-to-date survival estimates is not just an academic
exercise. It may help to prevent patients, their relatives
and clinicians from being unduly discouraged by outdated,
often too pessimistic survival figures. Period analysis of
survival, which should go along with efforts of high-quality
and up-to-date cancer registration, may make an
important contribution to this end.
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